Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Sector

Healthcare

Industry

Biotechnology

CEO

Greenleaf, Peter

Employees

130

Website

www.auriniapharma.com

IPO Date

2014-09-03

Headquarters

#140, 14315 – 118 Avenue, Edmonton, Alberta, T5L 4S6, Canada

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Aurinia Pharmaceuticals AUPH

Aurinia Pharmaceuticals Earnings Call Summary

Aurinia Pharmaceuticals Earnings

Transcripts

Events

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals
AUPH